Related Experiment Video
Updated: Aug 30, 2025

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
Potential Ophthalmological Side Effects Induced by Anti-Neoplastic Regimens for the Treatment of Genitourinary
Minas Sakellakis1, Nikolaos Spathas2, Konstantinos T Tsaousis3
1Medical Oncology, Hellenic Genitourinary Cancer Group, Athens, GRC.
Abstract:
The outcomes of patients with genitourinary (GU) cancers have been steadily improving in recent years. Novel therapies have entered our armamentarium, while several other regimens are currently being studied in clinical trials. This recent explosion of new agents has improved patient survival and the quality of life for patients, but has also significantly increased the frequency of several side effects. The current review will focus on the potential ocular adverse reactions of GU neoplastic treatments. The broad spectrum of manifestations of ocular toxicity underscores the uniqueness and complexity of the anatomic, physiologic, and metabolic features of the human eye. Most side effects are mild in severity and transient, but some can be severe, disabling, and irreversible. Clinicians should be aware of complications that might be vision threatening and impact the patient's quality of life. In this review, we focused on the ocular toxicity of the antineoplastic regimens that are currently used for the treatment of GU, including prostate cancer, bladder cancer, renal cell carcinoma, testicular cancer, pheochromocytoma, adrenocortical carcinoma, and penile cancer.
Insights
Novel cancer therapies improve genitourinary (GU) cancer outcomes but can cause ocular side effects. This review details potential vision-threatening eye complications from GU cancer treatments.
Area of Science:
- Ophthalmology
- Oncology
- Pharmacology
Background:
- Genitourinary (GU) cancers have seen improved patient outcomes due to novel therapies.
- New antineoplastic agents enhance survival and quality of life but increase side effect frequency.
Purpose of the Study:
- To review potential ocular adverse reactions associated with genitourinary cancer treatments.
- To highlight the spectrum of ocular toxicities from novel GU cancer therapies.
Main Methods:
- Literature review of ocular toxicity associated with antineoplastic regimens for GU cancers.
- Focus on treatments for prostate, bladder, renal cell, testicular, pheochromocytoma, adrenocortical, and penile cancers.
Main Results:
- Ocular toxicity from GU cancer treatments presents a broad spectrum of manifestations.
- While many side effects are mild and transient, some can be severe, disabling, or irreversible.
- Clinicians must recognize vision-threatening complications impacting patient quality of life.
Conclusions:
- Ocular adverse events are an important consideration in GU cancer treatment.
- Awareness of potential eye complications is crucial for managing patients on novel antineoplastic therapies.
- Early detection and management of ocular toxicity can preserve vision and quality of life.
Related Concept Videos
Nursing Assessment of the Genitourinary System I: Health History
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Kidney Transplant II: Surgical Procedure
Glaucoma: Overview
Kidney Transplant III: Nursing Management

